---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-025408"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:00:00.754710+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics FY2023 net loss $235.9M; positive DM1/DMD data and $345M offering extend runway to 2025

## Summary
- Q4 net loss $66.6M ($1.09/shr) vs $38.8M ($0.74/shr) YoY; FY2023 net loss $235.9M ($3.95/shr).
- Cash, equivalents and securities $123.1M at 12/31/23; Jan 2024 $345M public offering (net ~$323.9M) extends runway through 2025.
- Initial ACHIEVE (DM1) data: dose-dependent splicing correction and functional myotonia improvement at 1.8 mg/kg dose.
- Initial DELIVER (DMD exon 51) data: dystrophin expression exceeded eteplirsen with 24-fold lower total PMO dose; favorable safety.
- Plan to report higher-dose cohort data from both trials in H2 2024; goal to initiate registrational cohorts by end of 2024.

## SEC filing metadata
- accession: 0000950170-24-025408
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/0000950170-24-025408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/dyn-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-025408
- JSON: https://secwatch.observer/filing/0000950170-24-025408.json
- Plain text: https://secwatch.observer/filing/0000950170-24-025408.txt

## Key facts
- Earnings Releases
  Dyne Therapeutics, Inc. reported the fourth quarter and full year 2023 results: net income Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share, EPS $1.09 per basic and diluted share.
  - Period: the fourth quarter and full year 2023
  - Net income: Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share
  - EPS: $1.09 per basic and diluted share
  - Result: reported results
  source text: Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/0000950170-24-025408-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.